Illumina, Inc. (ILMN)

Over the past year, this Zacks Rank #3 (Hold) stock has surged 68.3%, well ahead of the industry’s16.3% growth and the S&P 500 composite’s rise of 29.5%. The renowned biotechnology company has a market capitalization of $21.41 billion. ILMN’s earnings yield of 3.7% is well ahead of the ...

Illumina has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 15% to $140.33 per share while the index has gained 13.3%.

Over the past year, this Zacks Rank #3 (Hold) stock has surged 68.3%, well ahead of the industry’s16.3% growth and the S&P 500 composite’s rise of 29.5%. The renowned biotechnology company has a market capitalization of $21.41 billion. ILMN’s earnings yield of 3.7% is well ahead of the ...

Illumina stock jumps after Q1 earnings and revenue beat, with margin expansion and raised 2026 outlook signaling continued growth momentum.

We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ILMN.